Review





Similar Products

photo click compound  (Enamine Ltd)
93
Enamine Ltd photo click compound
Photo Click Compound, supplied by Enamine Ltd, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/photo click compound/product/Enamine Ltd
Average 93 stars, based on 1 article reviews
photo click compound - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
quinuclidin 3 one quaternary ammonium compounds qo c12  (ATCC)
96
ATCC quinuclidin 3 one quaternary ammonium compounds qo c12
Quinuclidin 3 One Quaternary Ammonium Compounds Qo C12, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/quinuclidin 3 one quaternary ammonium compounds qo c12/product/ATCC
Average 96 stars, based on 1 article reviews
quinuclidin 3 one quaternary ammonium compounds qo c12 - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
compound 1 3  (Tokyo Chemical Industry)
86
Tokyo Chemical Industry compound 1 3
Compound 1 3, supplied by Tokyo Chemical Industry, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compound 1 3/product/Tokyo Chemical Industry
Average 86 stars, based on 1 article reviews
compound 1 3 - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
diabzi compound 3  (InvivoGen)
95
InvivoGen diabzi compound 3
Diabzi Compound 3, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/diabzi compound 3/product/InvivoGen
Average 95 stars, based on 1 article reviews
diabzi compound 3 - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
molecule compound rcm1 2 2 oxo 2 thiophen 2 yl ethyl sulfanyl 4 6 di thiophen 2 yl pyridine 3 carbonitrile  (Vitas-M Laboratory Ltd)
86
Vitas-M Laboratory Ltd molecule compound rcm1 2 2 oxo 2 thiophen 2 yl ethyl sulfanyl 4 6 di thiophen 2 yl pyridine 3 carbonitrile
The combination of <t>RCM1-NP</t> FA and venetoclax decreases tumor growth and enhances caspase-mediated apoptosis in a murine RMS model. (A) Schematic diagram of tumor cells inoculation and treatment. The figure is created in BioRender. Merjaneh, N. (2024) https://BioRender.com/z67t342 . (B) Combination therapy significantly reduced tumor burden compared with vehicle. The mean vehicle tumor volume on day 21 was 685 mm 3 , compared with the average tumor volume of the combination therapy of 361 mm 3 . The maximum tumor diameter was 17.3×11.5 mm and the corresponding maximum tumor volume was 1,144 mm 3 . Tumor volume was measured at different time points during the experiment (P≤0.01; n=12). (C) Combination therapy inhibited proliferation, as indicated by the decreased number of Ki67-positive cells. Combination therapy increased apoptosis, shown by the increased number of (D) BAX-positive cells and (E) the number of caspase3-positive cells compared with single agents and/or vehicle. A total of five random fields per sample were used to quantify the number of Ki67, BAX and cleaved caspase 3 positive cells per group. Values are shown as mean ± SD. Scale bar, 10 μ m. * P≤0.05, ** P≤0.01, **** P≤0.0001. RMS, rhabdomyosarcoma.
Molecule Compound Rcm1 2 2 Oxo 2 Thiophen 2 Yl Ethyl Sulfanyl 4 6 Di Thiophen 2 Yl Pyridine 3 Carbonitrile, supplied by Vitas-M Laboratory Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/molecule compound rcm1 2 2 oxo 2 thiophen 2 yl ethyl sulfanyl 4 6 di thiophen 2 yl pyridine 3 carbonitrile/product/Vitas-M Laboratory Ltd
Average 86 stars, based on 1 article reviews
molecule compound rcm1 2 2 oxo 2 thiophen 2 yl ethyl sulfanyl 4 6 di thiophen 2 yl pyridine 3 carbonitrile - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
pacs  (National Research Council Canada)
93
National Research Council Canada pacs
The combination of <t>RCM1-NP</t> FA and venetoclax decreases tumor growth and enhances caspase-mediated apoptosis in a murine RMS model. (A) Schematic diagram of tumor cells inoculation and treatment. The figure is created in BioRender. Merjaneh, N. (2024) https://BioRender.com/z67t342 . (B) Combination therapy significantly reduced tumor burden compared with vehicle. The mean vehicle tumor volume on day 21 was 685 mm 3 , compared with the average tumor volume of the combination therapy of 361 mm 3 . The maximum tumor diameter was 17.3×11.5 mm and the corresponding maximum tumor volume was 1,144 mm 3 . Tumor volume was measured at different time points during the experiment (P≤0.01; n=12). (C) Combination therapy inhibited proliferation, as indicated by the decreased number of Ki67-positive cells. Combination therapy increased apoptosis, shown by the increased number of (D) BAX-positive cells and (E) the number of caspase3-positive cells compared with single agents and/or vehicle. A total of five random fields per sample were used to quantify the number of Ki67, BAX and cleaved caspase 3 positive cells per group. Values are shown as mean ± SD. Scale bar, 10 μ m. * P≤0.05, ** P≤0.01, **** P≤0.0001. RMS, rhabdomyosarcoma.
Pacs, supplied by National Research Council Canada, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pacs/product/National Research Council Canada
Average 93 stars, based on 1 article reviews
pacs - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
compound 3  (Tokyo Chemical Industry)
86
Tokyo Chemical Industry compound 3
The combination of <t>RCM1-NP</t> FA and venetoclax decreases tumor growth and enhances caspase-mediated apoptosis in a murine RMS model. (A) Schematic diagram of tumor cells inoculation and treatment. The figure is created in BioRender. Merjaneh, N. (2024) https://BioRender.com/z67t342 . (B) Combination therapy significantly reduced tumor burden compared with vehicle. The mean vehicle tumor volume on day 21 was 685 mm 3 , compared with the average tumor volume of the combination therapy of 361 mm 3 . The maximum tumor diameter was 17.3×11.5 mm and the corresponding maximum tumor volume was 1,144 mm 3 . Tumor volume was measured at different time points during the experiment (P≤0.01; n=12). (C) Combination therapy inhibited proliferation, as indicated by the decreased number of Ki67-positive cells. Combination therapy increased apoptosis, shown by the increased number of (D) BAX-positive cells and (E) the number of caspase3-positive cells compared with single agents and/or vehicle. A total of five random fields per sample were used to quantify the number of Ki67, BAX and cleaved caspase 3 positive cells per group. Values are shown as mean ± SD. Scale bar, 10 μ m. * P≤0.05, ** P≤0.01, **** P≤0.0001. RMS, rhabdomyosarcoma.
Compound 3, supplied by Tokyo Chemical Industry, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compound 3/product/Tokyo Chemical Industry
Average 86 stars, based on 1 article reviews
compound 3 - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
phase 3 obesity compound  (Pfizer Inc)
86
Pfizer Inc phase 3 obesity compound
The combination of <t>RCM1-NP</t> FA and venetoclax decreases tumor growth and enhances caspase-mediated apoptosis in a murine RMS model. (A) Schematic diagram of tumor cells inoculation and treatment. The figure is created in BioRender. Merjaneh, N. (2024) https://BioRender.com/z67t342 . (B) Combination therapy significantly reduced tumor burden compared with vehicle. The mean vehicle tumor volume on day 21 was 685 mm 3 , compared with the average tumor volume of the combination therapy of 361 mm 3 . The maximum tumor diameter was 17.3×11.5 mm and the corresponding maximum tumor volume was 1,144 mm 3 . Tumor volume was measured at different time points during the experiment (P≤0.01; n=12). (C) Combination therapy inhibited proliferation, as indicated by the decreased number of Ki67-positive cells. Combination therapy increased apoptosis, shown by the increased number of (D) BAX-positive cells and (E) the number of caspase3-positive cells compared with single agents and/or vehicle. A total of five random fields per sample were used to quantify the number of Ki67, BAX and cleaved caspase 3 positive cells per group. Values are shown as mean ± SD. Scale bar, 10 μ m. * P≤0.05, ** P≤0.01, **** P≤0.0001. RMS, rhabdomyosarcoma.
Phase 3 Obesity Compound, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phase 3 obesity compound/product/Pfizer Inc
Average 86 stars, based on 1 article reviews
phase 3 obesity compound - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

Image Search Results


The combination of RCM1-NP FA and venetoclax decreases tumor growth and enhances caspase-mediated apoptosis in a murine RMS model. (A) Schematic diagram of tumor cells inoculation and treatment. The figure is created in BioRender. Merjaneh, N. (2024) https://BioRender.com/z67t342 . (B) Combination therapy significantly reduced tumor burden compared with vehicle. The mean vehicle tumor volume on day 21 was 685 mm 3 , compared with the average tumor volume of the combination therapy of 361 mm 3 . The maximum tumor diameter was 17.3×11.5 mm and the corresponding maximum tumor volume was 1,144 mm 3 . Tumor volume was measured at different time points during the experiment (P≤0.01; n=12). (C) Combination therapy inhibited proliferation, as indicated by the decreased number of Ki67-positive cells. Combination therapy increased apoptosis, shown by the increased number of (D) BAX-positive cells and (E) the number of caspase3-positive cells compared with single agents and/or vehicle. A total of five random fields per sample were used to quantify the number of Ki67, BAX and cleaved caspase 3 positive cells per group. Values are shown as mean ± SD. Scale bar, 10 μ m. * P≤0.05, ** P≤0.01, **** P≤0.0001. RMS, rhabdomyosarcoma.

Journal: International Journal of Oncology

Article Title: FOXM1 inhibitor, RCM-1, enhances venetoclax mediated apoptosis through downregulation of ATP2B4 in rhabdomyosarcoma

doi: 10.3892/ijo.2026.5865

Figure Lengend Snippet: The combination of RCM1-NP FA and venetoclax decreases tumor growth and enhances caspase-mediated apoptosis in a murine RMS model. (A) Schematic diagram of tumor cells inoculation and treatment. The figure is created in BioRender. Merjaneh, N. (2024) https://BioRender.com/z67t342 . (B) Combination therapy significantly reduced tumor burden compared with vehicle. The mean vehicle tumor volume on day 21 was 685 mm 3 , compared with the average tumor volume of the combination therapy of 361 mm 3 . The maximum tumor diameter was 17.3×11.5 mm and the corresponding maximum tumor volume was 1,144 mm 3 . Tumor volume was measured at different time points during the experiment (P≤0.01; n=12). (C) Combination therapy inhibited proliferation, as indicated by the decreased number of Ki67-positive cells. Combination therapy increased apoptosis, shown by the increased number of (D) BAX-positive cells and (E) the number of caspase3-positive cells compared with single agents and/or vehicle. A total of five random fields per sample were used to quantify the number of Ki67, BAX and cleaved caspase 3 positive cells per group. Values are shown as mean ± SD. Scale bar, 10 μ m. * P≤0.05, ** P≤0.01, **** P≤0.0001. RMS, rhabdomyosarcoma.

Article Snippet: The small molecule compound RCM1 (2-[2-oxo-2-(thiophen-2-yl) ethyl]sulfanyl-4,6-di(thiophen-2-yl) pyridine-3-carbonitrile) was synthesized by Vitas-M Laboratory (95% purity) and dissolved in DMSO for in vitro studies.

Techniques: